2018 International Congress

October 5-9, 2018. Hong Kong. Abstracts are presented on the 6th, 7th, and 8th.

View by Title View Sessions

View by Date

Saturday, October 6, 2018

1:45pm-3:15pm: Training in parkinsonism among health providers in Cameroon

M. Kurtis, M. Monje, C. Delgado-Suarez, I. Garcia-Morales, P. Gomez-Iglesias, M. Molina, D. Garcia-Azorin (Madrid, Spain)

Education in Movement Disorders · Hall 3FG

1:45pm-3:15pm: Transient dystonia of infancy: 25 cases

V. Naranjo, M. Troncoso, A. Barrios, L. Troncoso, S. Witting, S. Lara, D. Muñoz, M. Hidalgo, I. Ruiz (Santiago, Chile)

Pediatric Movement Disorders · Hall 3FG

1:45pm-3:15pm: Transplantation therapy of human iPS cell-derived dopamine neural progenitor cells for Parkinson’s disease

R. Nakamura, G. Oyama, T. Jo, K. Ishikawa, R. Nonaka, Y. Shimo, W. Akamatsu, N. Hattori (Tokyo, Japan)

Therapy in Movement Disorders: Gene and Cell-Based Therapies · Hall 3FG

1:45pm-3:15pm: Treatment of Levodopa Dose Failure with Subcutaneous Apomorphine Injection

S. Isaacson (Boca Raton, FL, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Treatment with levodopa/carbidopa intestinal gel of advanced Parkinson’s disease patients: Bulgarian experience

E. Chorbadzhieva (Sofia, Bulgaria)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: TreCap: Quantify and assess tremor in real-time with a new wearable device

R. Bremm, J. Goncalves, K. Koch, F. Hertel (Belvaux, Luxembourg)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Unusual eye movement found in antineuronal nuclear autoantibody type 2 (ANNA-2); both seesaw nystagmus and opsoclonus may provide a novel mechanism

M. Rizvi, L. Cameron, A. Shaikh, C. Kilbane (Cleveland, OH, USA)

Pathophysiology (Other Movement Disorders) · Hall 3FG

1:45pm-3:15pm: Update on The Personalized Parkinson Project: Partnering with Patients to Understand Disease Progression Through a Multi-Dimensional Approach

B. Bloem, R. Kapur, T. v/d Zande, M. Faber, W. Marks, Jr (Nijmegen, Netherlands)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Use of safinamide: A clinical practice review of 2 year experience

C. Borrue-Fernandez (San Sebastian Reyes, Spain)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Using tablet devices to educate patients about dystonia and botulinum toxin for movement disorders

S. Bobker, A. Hanineva, P. Popa, H. Ellsworth, X. Wu, I. Diaz, N. Hellmers, C. Henchcliffe, H. Sarva (New York, NY, USA)

Education in Movement Disorders · Hall 3FG